Skip to main content
QURE
NASDAQ Life Sciences

uniQure Prices Upsized $258.7M Public Offering at $45.50/Share, Underwriters Exercise Option in Full

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$49.24
Mkt Cap
$3.055B
52W Low
$8.73
52W High
$71.5
52W Position info
464% above low
Off High info
31% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73 on elevated volume (2.2× avg).

Summary

uniQure N.V. priced an upsized public offering of ordinary shares, raising approximately $242.7 million in net proceeds at $45.50 per share, with underwriters fully exercising their option for additional shares.


Key Events · Financing and Capital Events · QURE

  • Upsized Public Offering Priced

    uniQure priced an offering of 4,945,055 ordinary shares at $45.50 per share, totaling $225 million in gross proceeds for the firm shares. This finalizes terms of an offering initiated on 2026-06-22.

  • Underwriters Fully Exercise Option

    Underwriters fully exercised their option on June 24, 2026, to purchase an additional 741,758 ordinary shares, bringing the total gross offering to approximately $258.7 million.

  • Significant Capital Raise

    The company expects to receive approximately $242.7 million in net proceeds, providing substantial funding for its operations and commercialization plans.

  • Moderate Discount

    The offering price of $45.50 per share represents a moderate discount of approximately 7.6% compared to the current stock price of $49.24.


Analysis · QURE · Life Sciences

uniQure N.V. has finalized the pricing of its public offering, raising approximately $242.7 million in net proceeds. The offering was upsized from a previously announced $150 million to $225 million for firm shares, with an additional 741,758 shares purchased by underwriters through a fully exercised option, bringing the total gross offering to approximately $258.7 million. The shares were priced at $45.50, representing a moderate discount to the current market price. This substantial capital raise, representing nearly 8% of the company's market capitalization, provides critical funding for the company's operations and commercialization efforts, especially following recent regulatory developments for its Huntington's disease gene therapy, AMT-130.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $49.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $22.99 info
Change: +$0.3915 (+2%) info
Market Cap: $1.598B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $22.99 info
Change: +$0.550 (+2%) info
Market Cap: $1.598B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $22.99 info
Change: -$4.67 (-17%) info
Market Cap: $1.598B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $22.99 info
Change: +$0.990 (+4%) info
Market Cap: $1.598B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $22.99 info
Change: +$0.790 (+4%) info
Market Cap: $1.598B info